In the present study, we found that the CBP/p300 dual inhibitor CP-C27 showed higher selectivity and potency than tazemetostat in SMARCB1-deficient cells, indicating that CBP/p300 dual inhibitors such as CP-C27 may be promising treatments for SMARCB1-deficient cancers. This evidence concerns the gene SMARCB1 and cancer.